Skip to main
BLSM

BLSM Stock Forecast & Price Target

BLSM Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 60%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

BlossomHill Therapeutics is a biopharmaceutical company focused on developing precision oncology treatments. With a promising pipeline and successful collaborations, they are well-positioned for growth in the biotech market. However, investors should be aware of the potential risks and volatility of the industry, as well as the uncertainties surrounding drug approvals and regulations. Despite these factors, BlossomHill shows potential for long-term success and growth in the lucrative cancer treatment market.

Bears say

BlossomHill Therapeutics is heavily reliant on its lead candidate, BH-30643, for future revenue generation and success, which has promising early results in TKI-naïve NSCLC patients with classical EGFR mutations. However, the company's potential success is not guaranteed, and additional capital may be needed in the future to fund operations. Risks associated with drug pricing and the fact that BlossomHill has never been profitable also contribute to this negative outlook.

BLSM has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 60% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Blossomhill Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Blossomhill Therapeutics Inc (BLSM) Forecast

Analysts have given BLSM a Buy based on their latest research and market trends.

According to 5 analysts, BLSM has a Buy consensus rating as of Sep 16, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $32.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $32.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Blossomhill Therapeutics Inc (BLSM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.